Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Publisher



Alavian SM^{1, 2} ; Hajarizadeh B³ ; Lankarani KB⁴ ; Sharafi H^{1, 2} ; Daryani NE⁵ ; Merat S⁶ ; Mohraz M⁷ ; Mardani M⁸ ; Fattahi MR⁹ ; Poustchi H⁶ ; Nikbin M² ; Nabavi M¹⁰ ; Adibi P¹¹ ; Ziaee M¹² Show All Authors Show Affiliations
Source: Hepatitis Monthly Published:2016

Abstract

Context: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran. Evidence Acquisition: The recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, ScopusandWeb of Science. Expert opinionwasbasedonthe consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016. Results: Pegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. InHCVgenotype 1 and 4, DCV/SOF and LDV/SOF are recommended. InHCVgenotype 2, SOF plus RBV and inHCVgenotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered. Conclusions: Affordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection. © 2016, Kowsar Corp.